PharmaCyte Biotech shares surge 29.98% premarket driven by FDA approval optimism and $6.7M cash boost from Femasys stake monetization.

PharmaCyte Biotech surged 29.98% in premarket trading, driven by FDA-related optimism and a $6.7 million cash infusion from monetizing its stake in Femasys, which boosted liquidity to $20 million. The stock’s rally reflects market validation of its strategic capital deployment and speculative interest in unconfirmed cancer therapy advancements. While the company reported an $8.36 million net loss, the liquidity gain and regulatory focus underscore short-term investor enthusiasm amid broader biotech sector volatility.